Affordable Access

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

Authors
  • 1
  • 1 Department of Medicine, University of Pittsburgh, Pennsylvania, USA. [email protected]
Type
Published Article
Journal
Cancer
Publication Date
Volume
95
Issue
5
Pages
1101–1112
Identifiers
PMID: 12209697
Source
Medline

Abstract

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments